CN108310123A - A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia - Google Patents
A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia Download PDFInfo
- Publication number
- CN108310123A CN108310123A CN201810265726.6A CN201810265726A CN108310123A CN 108310123 A CN108310123 A CN 108310123A CN 201810265726 A CN201810265726 A CN 201810265726A CN 108310123 A CN108310123 A CN 108310123A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- pharmaceutical composition
- rosa roxburghii
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 240000002547 Rosa roxburghii Species 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 235000000640 Rosa roxburghii Nutrition 0.000 claims abstract description 19
- 201000005569 Gout Diseases 0.000 claims abstract description 17
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 claims abstract description 15
- 235000020339 pu-erh tea Nutrition 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000009636 Huang Qi Substances 0.000 claims abstract description 13
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 description 22
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 21
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 20
- 229940116269 uric acid Drugs 0.000 description 20
- 235000013616 tea Nutrition 0.000 description 14
- 241001122767 Theaceae Species 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- 241000229143 Hippophae Species 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002529 benzbromarone Drugs 0.000 description 5
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of pharmaceutical compositions and its preparation method and application for preventing and/or treating hyperuricemia, it is the preparation that the raw material matched containing following weight is prepared：30~50 parts of Rosa roxburghii Tratt, 10~30 parts of Pu'er tea, 10~30 parts of Radix Astragali.The composition further includes following raw material：5~20 parts of 10~30 parts of pueraria lobata and/or sea-buckthorn.The results show, compared with the drug of existing treatment hyperuricemia and gout, composition of the invention is more safe and effective, has a vast market application prospect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for preventing and/or treating hyperuricemia and preparation method thereof and use
On the way.
Background technology
Uric acid is the final product of human body purine metabolism, is mainly generated by liver metabolism, and kidney excretion goes out in vitro.Antihyperuricemic
Disease (hyperuricemia, HUA) is that uric acid is excessive or kidney excretion uric acid is reduced since liver metabolism generates in blood, or
The reason of the two has concurrently generates uric acid in blood level and increases, and even higher than blood uric acid generates saturated concentration (416.5 μ of crystallization
Mol/L pathological state).Patients with Hyperuricemia can be precipitated because of monosodium urate salt (monosodium, MSU) crystal and gradually accumulate
It is tired to induce gout, it is also possible to symptom do not occur, but the uric acid total amount of patient's body will be apparently higher than normal person in the case of two kinds
Group.In recent years, with the improvement of people's living standards, the change of dietary structure and living habit, the illness rate of hyperuricemia
Increase year by year, epidemiological study data shows that the morbidity of hyperuricemia and primary gout is in rising trend, in China,
Through there is 1.2 hundred million HUA crowd, the 10% of total population is accounted about, person in middle and old age and postclimacteric women are group of people at high risk, are sent out in recent years
The sick age is also in the trend of rejuvenation.
Currently, the drug of clinical treatment hyperuricemia is generally divided into three classes.(1) releasing uric acid prescription medicine：Uricosuric
Include mainly probenecid, Sulfinpyrazone, Benzbromarone etc..Such drug can prevent reabsorption of the renal tubule to uric acid, increase urine
The discharge of acid, to play the role of reducing serum uric acid level in human body, also human body while side effect multiple rows of uric acid
Other trace elements also excrete, and can cause low blood sodium, Diagnostic value, low blood calcium, so use cannot be grown, but also to liver, kidney
There is side effect, use can not be grown.(2) drug for inhibiting uric acid to generate：The drug for clinically commonly uric acid being inhibited to generate is other
Fast alcohol, the medicine are a kind of purine oxidase inhibitor of strength, can effectively reduce uric acid and generate, reduce uric acid level in human body
Drug, but Allopurinol has the side effects such as the systemic allergics symptoms such as generation fash, poisoning syndrome, bone marrow suppression, hepatic injury,
It is very careful using upper requirement.(3) drug of alkalized urine：The alkalinity medicine such as sodium bicarbonate, potassium citrate and citron mixture acid
Object this acted on without anti-trioxypurine but can alkalized urine, increase solubility of the uric acid in blood, uric acid made to be not easy to gather and shape in urine
At crystallization.Calculus urate action speed is treated in phleboclysis, and common drug has sodium lactate solution and 5% sodium bicarbonate molten
Liquid, due to the use of when need close observation blood pressure situations such as, it is therefore desirable to hospitalization；Oral sodium bicarbonate is the most convenient, still
May easily cause and have a stomach upset, before beging half an hour be administered at empty stomach, because stomach is acidic environment, especially feed after be even more such as
This, and in stomach long-time indwelling stomach, at this moment such as eating sodium bicarbonate alkaline drug can neutralize with hydrochloric acid in gastric juice quickly, can not absorb
Enter blood and flow into kidney alkalized urine, and many gases generated keep stomach more glutted, the people if any stomach trouble such as gastric ulcer is easy
Bleeding and perforation.
Therefore, it is badly in need of a kind of safe, treatment hyperuricemia without side-effects drug now.
Invention content
In order to solve the above technical problem, the present invention provides a kind of medicines for preventing and/or treating hyperuricemia
Compositions, it is the preparation that the raw material matched containing following weight is prepared：30~50 parts of Rosa roxburghii Tratt, Pu'er tea 10~30
Part, 10~30 parts of Radix Astragali.
Further, it is the preparation that the raw material matched containing following weight is prepared：40 parts of Rosa roxburghii Tratt, Pu'er tea 20
Part, 20 parts of Radix Astragali.
Further, described pharmaceutical composition further includes following raw material：5~20 parts of 10~30 parts of pueraria lobata and/or sea-buckthorn.
Further, the pueraria lobata is 20 parts, and the sea-buckthorn is 10 parts.
Further, the Rosa roxburghii Tratt is rose family rose rosa roxburghii Rosa roxburghii Tratt and single-lobe
The fruit of rosa roxburghii.
Further, it is active constituent that it, which is by the medicinal powder of bulk pharmaceutical chemicals, the water of bulk pharmaceutical chemicals or extractive with organic solvent, in addition
The preparation that acceptable auxiliary material or complementary ingredient are prepared in pharmacy.
Further, the preparation is oral preparation；Preferably, the oral preparation is decoction, powder, capsule, piece
Agent, granule.
The present invention also provides a kind of methods preparing aforementioned pharmaceutical compositions, it includes the following steps：
1) each raw material is weighed by weight ratio；
2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, and in pharmacy acceptable auxiliary material or it is complementary at
Divide and is prepared into preparation.
The present invention also provides above-mentioned compositions to prepare the purposes in preventing and/or treating the drug of hyperuricemia.
The present invention also provides above-mentioned compositions to prepare the purposes in preventing and/or treating the drug of gout.
The results show, compared with the drug of existing treatment hyperuricemia and gout, composition of the invention is more
Safely and effectively, application prospect is had a vast market.
Obviously, the above according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific implementation mode of form by the following examples remakes further specifically the above of the present invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on the above of the present invention
The technology realized all belongs to the scope of the present invention.
Specific implementation mode
The preparation of embodiment 1, pharmaceutical composition of the present invention
It since tea bag is across tea beverage, health products, three big gold industry of medicinal herb tea, can not only sip tea, but also energy health care, and can support
It is raw.It is specific as follows the following provide the preparation method of teabag of food of the present invention, health products or pharmaceutical composition：
1 prescription：Rosa roxburghii Tratt 40g, Pu'er tea 20g, Radix Astragali 20g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 2, pharmaceutical composition of the present invention
1 prescription：Rosa roxburghii Tratt 40g, Pu'er tea 20g, Radix Astragali 20g, pueraria lobata 20g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 3, pharmaceutical composition of the present invention
1 prescription：Rosa roxburghii Tratt 40g, Pu'er tea 20g, Radix Astragali 20g, sea-buckthorn 10g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 4, pharmaceutical composition of the present invention
1 prescription：Rosa roxburghii Tratt 40g, Pu'er tea 20g, Radix Astragali 20g, pueraria lobata 20g, sea-buckthorn 10g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 5, pharmaceutical composition of the present invention
1 prescription：Rosa roxburghii Tratt 30g, Pu'er tea 10g, Radix Astragali 10g, pueraria lobata 10g, sea-buckthorn 5g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 6, pharmaceutical composition of the present invention
1 prescription：Rosa roxburghii Tratt 50g, Pu'er tea 30g, Radix Astragali 30g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 7, pharmaceutical composition of the present invention
1 prescription：Rosa roxburghii Tratt 50g, Pu'er tea 30g, Radix Astragali 30g, pueraria lobata 30g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
The preparation of embodiment 8, pharmaceutical composition of the present invention
1 prescription：Rosa roxburghii Tratt 50g, Pu'er tea 30g, Radix Astragali 30g, sea-buckthorn 20g
2 preparation methods：Each raw material of recipe quantity, mixing is taken to beat powder, sieve with 100 mesh sieve, all after mixing, by every bag of 3-
5g is dispensed, and tea bag is made in irradiation sterilization.
3 occupation modes：One day 3 bags, brewed with water it is i.e. drinkable, it is each primary in the morning, afternoon and evening.
Illustrate beneficial effects of the present invention below by way of the mode of test example.
Test example 1, hyperuricemia clinical case statistics
(1) patient criteria is accepted for medical treatment
Patients with Hyperuricemia, 30-70 years old ages, male 50, women 30.
(2) diagnostic criteria of hyperuricemia
Under normal purine diet state, non-empty stomach serum uric acid level male twice on the same day>416 μm of ol/L (7mg/dl),
Women>357 μm of ol/L (6mg/dl), as hyperuricemia.
(3) standard is treated
It is effective：Testing the empty stomach serum uric acid level of Patients Before And After reduces by 35% or more.
Effectively：Testing the empty stomach serum uric acid level of Patients Before And After reduces by 20% or more.
In vain：The empty stomach serum uric acid level of Patients Before And After is tested without reduction.
(4) therapy
1) medication：After clarifying a diagnosis, treatment group is treated using composition prepared by the embodiment of the present invention 4；It is right
It is treated using benzbromarone tablets according to group.
Treatment group：40 patients are all made of following drug：Rosa roxburghii Tratt 40g, Pu'er tea 20g, pueraria lobata 20g, sea-buckthorn 10g.It prepares
Process：Above-mentioned each raw material is weighed, mixing is beaten powder, is sieved with 100 mesh sieve, and all after mixing, is dispensed by every bag of 3g, irradiation sterilization,
Tea bag is made.Application method：Boiling water is taken after mixing it with water, and three times a day, 1 bag every time, 12 weeks as a treatment course.
Control group：Benzbromarone tablets, 50mg*10 pieces, Kunshan dragon lantern Rui Di pharmaceutical Co. Ltds, lot number 161005.It uses
Method：Oral 50mg (1) every time, once a day, early to take after the meal, 3 weeks as a treatment course.
2) without apparent medication taboo, without other complications.
(5) treatment results
Treatment time：12 weeks
Efficacy determination：The results are shown in Table 1
1 hyperuricemia Comparison of therapeutic table of table
From the above it is found that the pharmaceutical composition of the present invention is suitable with the therapeutic effect of benzbromarone tablets, but take
After benzbromarone tablets, often there is digestive discomfort sense (such as nausea, vomitting, feeling of repletion and diarrhea etc. in stomach), scratchiness, face in patient
The adverse reactions such as face is rubescent, erythema, photoallergy, edema, precordial region sense of discomfort.And after taking the pharmaceutical composition of the present invention,
Patient is not in any adverse reaction.Therefore, compared with existing drug, pharmaceutical composition of the invention is safer.
Test example 2, gout clinical case statistics
(1) patient criteria is accepted for medical treatment
Patient with gout, 23-70 years old ages, male 47, women 40
(2) diagnostic criteria of gout
The gout contingency table released with reference to American society of rheumatism in 2015 and European rheumatism alliance ACR/Eular joints
Standard, criteria for classification include 3 projects, and 8 entries amount to 23 points, but need to only meet 8 points can be diagnosed as gout, and details are shown in Table 2：
2 gout diagnostic criteria of table
(3) standard is treated
It is effective：Gout score value reduces by 40%.
Effectively：Gout score value reduces by 20%.
In vain：Gout score value is without reduction.
(4) therapy
1) medication：After clarifying a diagnosis, treatment group is treated using composition prepared by the embodiment of the present invention 4；It is right
Effects of Colchicine In Treating is used according to group.
Treatment group：44 patients are all made of following drug：Rosa roxburghii Tratt 40g, Pu'er tea 20g, pueraria lobata 20g, sea-buckthorn 10g.It prepares
Process：Above-mentioned each raw material is weighed, mixing is beaten powder, is sieved with 100 mesh sieve, and all after mixing, is dispensed by every bag of 5g, irradiation sterilization,
Tea bag is made.Application method：Boiling water is taken after mixing it with water, and three times a day, 1 bag every time, 5 weeks as a treatment course.
Control group：Colchicines tablets, 0.5mg*20 pieces, Yunnan Plant Pharmaceutical Industry Co., Ltd., lot number 20170202.User
Method：Acute stage：Adult's usual amounts are to take 0.5~1mg (1~2) in every 1~2 hour, until joint symptoms are alleviated, or abdomen occur
It rushes down or vomits, reach therapeutic dose and be generally 3~5mg (6~10), no more than 6mg (12) in 24 hours, withdraw 72 hours
Afterwards daily dose be 0.5-1.5mg (1~3), part vic, totally 7 days.Prevent：0.5~1mg (1~2) on the one takes by several times
With.
2) without apparent medication taboo, without other complications.
(5) treatment results
Treatment time：12 weeks
Efficacy determination：The results are shown in Table 3
3 gout Comparison of therapeutic table of table
From the above it is found that the pharmaceutical composition of the present invention is better than the therapeutic effect of colchicines tablets, and the present invention
Composition have no toxic side effect, safety.
To sum up, compared with the drug of existing treatment hyperuricemia and gout, composition of the invention is more safe and effective,
Have a vast market application prospect.
Claims (10)
1. a kind of pharmaceutical composition for preventing and/or treating hyperuricemia, it is characterised in that：It is containing following weight
The preparation that the raw material of proportioning is prepared：30~50 parts of Rosa roxburghii Tratt, 10~30 parts of Pu'er tea, 10~30 parts of Radix Astragali.
2. pharmaceutical composition according to claim 1, it is characterised in that：It is prepared by the raw material matched containing following weight
Made of preparation：40 parts of Rosa roxburghii Tratt, 20 parts of Pu'er tea, 20 parts of Radix Astragali.
3. pharmaceutical composition according to claim 1 or 2, it is characterised in that：The composition further includes following raw material：Pueraria lobota
5~20 parts of 10~30 parts of root and/or sea-buckthorn.
4. pharmaceutical composition according to claim 3, it is characterised in that：The pueraria lobata is 20 parts, and the sea-buckthorn is 10 parts.
5. pharmaceutical composition according to claims 1 to 4, it is characterised in that：The Rosa roxburghii Tratt is rose family rose
The fruit of rosa roxburghii Rosa roxburghii Tratt and single-lobe rosa roxburghii.
6. according to Claims 1 to 5 any one of them pharmaceutical composition, it is characterised in that：It is medicinal powder by bulk pharmaceutical chemicals, original
Expect that the water of medicine or extractive with organic solvent are active constituent, and in pharmacy acceptable auxiliary material or complementary ingredient prepare and
At preparation.
7. according to claim 1~6 any one of them pharmaceutical composition, it is characterised in that：The preparation is oral preparation；It is excellent
Choosing, the oral preparation is decoction, powder, capsule, tablet, granule.
8. a kind of method preparing any one of claim 1~7 described pharmaceutical composition, it is characterised in that：It includes following step
Suddenly：
1) each raw material is weighed by weight ratio；
2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, in addition acceptable auxiliary material or complementary ingredient system in pharmacy
For at preparation.
9. any one of claim 1~7 composition is preparing the use in preventing and/or treating the drug of hyperuricemia
On the way.
10. any one of claim 1~7 composition is preparing the purposes in preventing and/or treating the drug of gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810265726.6A CN108310123A (en) | 2018-03-28 | 2018-03-28 | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810265726.6A CN108310123A (en) | 2018-03-28 | 2018-03-28 | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108310123A true CN108310123A (en) | 2018-07-24 |
Family
ID=62899511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810265726.6A Pending CN108310123A (en) | 2018-03-28 | 2018-03-28 | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108310123A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121144A (en) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
| CN118059205A (en) * | 2024-02-06 | 2024-05-24 | 贵州瑞诚新材料技术有限公司 | Roxburgh rose traditional Chinese medicine compound composition for reducing uric acid, process and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288212A (en) * | 2013-07-15 | 2015-01-21 | 王元英 | A traditional Chinese medicine composition for reducing purine |
| CN104322737A (en) * | 2014-10-10 | 2015-02-04 | 张成海 | Heart-nourishing health-care tea for old people to drink |
| CN105902687A (en) * | 2016-05-24 | 2016-08-31 | 姚德林 | Health-care tea for treating gout and preparation method thereof |
| CN106110247A (en) * | 2016-07-11 | 2016-11-16 | 贵州省从江县盈茂农业科技开发有限公司 | A kind of Chinese medicine formula treating gout |
-
2018
- 2018-03-28 CN CN201810265726.6A patent/CN108310123A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288212A (en) * | 2013-07-15 | 2015-01-21 | 王元英 | A traditional Chinese medicine composition for reducing purine |
| CN104322737A (en) * | 2014-10-10 | 2015-02-04 | 张成海 | Heart-nourishing health-care tea for old people to drink |
| CN105902687A (en) * | 2016-05-24 | 2016-08-31 | 姚德林 | Health-care tea for treating gout and preparation method thereof |
| CN106110247A (en) * | 2016-07-11 | 2016-11-16 | 贵州省从江县盈茂农业科技开发有限公司 | A kind of Chinese medicine formula treating gout |
Non-Patent Citations (5)
| Title |
|---|
| 中国特产大典编审委员会贵州卷编委会: "《中国特产大典贵州卷》", 31 March 2011, 贵州人民出版社 * |
| 史珅: "葛根提取物对高尿酸血症大鼠血尿酸的影响", 《食品科技》 * |
| 王友兰: "普洱茶提取物对高尿酸血症模型小鼠血尿酸的影响", 《内蒙古中医药》 * |
| 贵州省科学技术情报研究所，贵州省科技发展战略研究院: "《贵州省中药材大品种产业链 第1部》", 30 September 2017, 贵州科技出版社 * |
| 郭小李: "越桔黄酮对高尿酸血症的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121144A (en) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
| CN112121144B (en) * | 2020-09-20 | 2021-11-12 | 武汉宏博云智生物科技有限公司 | Roxburgh rose composition and preparation method and application thereof |
| CN118059205A (en) * | 2024-02-06 | 2024-05-24 | 贵州瑞诚新材料技术有限公司 | Roxburgh rose traditional Chinese medicine compound composition for reducing uric acid, process and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102670864B (en) | Medicine composition with antioxidant function for treating cardiovascular and cerebrovascular diseases and sugar diabetes | |
| KR101717893B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CN108882744A (en) | Contain intelligence development extract as effective component for preventing, improving or treating the composition of hyperuricemia or dysbolism relevant to hyperuricemia | |
| TWI269656B (en) | Therapeutical composition for hepatitis C | |
| CN106820151A (en) | A kind of bivalve compound health composition, preparation method and application | |
| JP2011522844A (en) | Composition for reducing blood glucose level and use thereof | |
| CN101199347A (en) | Pb excluding health care product and its preparation method | |
| CN108310123A (en) | A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| JP2005330273A (en) | Free radical-scavenging composition in living body | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| CN101427720A (en) | High-concentration infusion tea for treating diabetes and method of producing the same | |
| CN108420891A (en) | A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia | |
| US20220047658A1 (en) | Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications | |
| CN113712982B (en) | Composition for preventing or treating non-alcoholic fatty liver disease and obesity, and preparation method and application thereof | |
| CN112675194A (en) | Calcium supplement composition | |
| CN105616581A (en) | Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN104800686B (en) | A kind of pharmaceutical composition for treating sequelae of eating and drinking immoderately and its preparation method and application | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN112203651A (en) | Agent for preventing or improving nocturnal pollakisuria | |
| CN103877533B (en) | Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof | |
| KR100450055B1 (en) | Food composition for improving physical constitution containing seeds of bean plants as main components, and food produced therefrom | |
| CN108261511A (en) | A kind of composition with antiobesity action and preparation method thereof and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180724 |
|
| RJ01 | Rejection of invention patent application after publication |